Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Jun;111(6):692-704.
doi: 10.1007/s00392-022-01992-6. Epub 2022 Feb 26.

Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD)

Melissa Amrein #  1 , Xinmin S Li #  2 , Joan Walter  1   3 , Zeneng Wang  2 , Tobias Zimmermann  1   4 , Ivo Strebel  1 , Ursina Honegger  1 , Kathrin Leu  1 , Ibrahim Schäfer  1   4 , Raphael Twerenbold  1 , Christian Puelacher  1   4 , Noemi Glarner  1 , Thomas Nestelberger  1   5 , Luca Koechlin  1   6 , Benjamin Ceresa  1 , Philip Haaf  1 , Adam Bakula  1 , Michael Zellweger  1 , Stanley L Hazen  2   7 , Christian Mueller  8
Affiliations
Observational Study

Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD)

Melissa Amrein et al. Clin Res Cardiol. 2022 Jun.

Abstract

Background: Trimethylamine N-oxide (TMAO) has been associated with cardiovascular outcomes. However, the diagnostic value of TMAO and its precursors have not been assessed for functionally relevant coronary artery disease (fCAD) and its prognostic potential in this setting needs to be evaluated.

Methods: Among 1726 patients with suspected fCAD serum TMAO, and its precursors betaine, choline and carnitine, were quantified using liquid chromatography tandem mass spectrometry. Diagnosis of fCAD was performed by myocardial perfusion single photon emission tomography (MPI-SPECT) and coronary angiography blinded to marker concentrations. Incident all-cause death, cardiovascular death (CVD) and myocardial infarction (MI) were assessed during 5-years follow-up.

Results: Concentrations of TMAO, betaine, choline and carnitine were significantly higher in patients with fCAD versus those without (TMAO 5.33 μM vs 4.66 μM, p < 0.001); however, diagnostic accuracy was low (TMAO area under the receiver operating curve [AUC]: 0.56, 95% CI [0.53-0.59], p < 0.001). In prognostic analyses, TMAO, choline and carnitine above the median were associated with significantly (p < 0.001 for all) higher cumulative events for death and CVD during 5-years follow-up. TMAO remained a significant predictor for death and CVD even in full models adjusted for renal function (HR = 1.58 (1.16, 2.14), p = 0.003; HR = 1.66 [1.07, 2.59], p = 0.025). Prognostic discriminative accuracy for TMAO was good and robust for death and CVD (2-years AUC for CVD 0.73, 95% CI [0.65-0.80]).

Conclusion: TMAO and its precursors, betaine, choline and carnitine were significantly associated with fCAD, but with limited diagnostic value. TMAO was a strong predictor for incident death and CVD in patients with suspected fCAD.

Clinical trial registration: NCT01838148.

Keywords: Cardiovascular death; Functionally relevant coronary artery disease (fCAD); Gut microbiota; Incident major adverse cardiac events (mace); Myocardial infarction; Trimethylamine N-oxide (TMAO).

PubMed Disclaimer

Conflict of interest statement

Dr. Walter reports a research grant from the Swiss Academy of Medical Sciences and the Bangerter Foundation (YTCR 23/17). Dr. Twerenbold reports receiving research support from the Swiss National Science Foundation (P300PB_167803), the Swiss Heart Foundation, the Swiss Society of Cardiology, the University Hospital of Basel, as well as speaker honoraria/consulting honoraria from Roche Diagnostics, Abbott Diagnostics, Siemens, Singulex and Brahms. Dr. Nestelberger received speaker honoraria from Beckman-Coulter. Dr. Koechlin has received a research grant from the University of Basel, the Swiss Academy of Medical Sciences and the Gottfried and Julia Bangerter-Rhyner Foundation, as well as the “Freiwillige Akademische Gesellschaft Basel”, outside the submitted work. Professor Mueller reports receiving research support from the Swiss National Science Foundation, the Swiss Heart Foundation, the KTI, the European Union, the Stiftung für kardiovaskuläre Forschung Basel, the University of Basel, the University Hospital Basel, Abbott, Beckman Coulter, Biomerieux, Brahms, Ortho Diagnostics, Roche, Siemens, Singulex, Sphingotec, as well as speaker honoraria/consulting honoraria from Abbott, Amgen, Astra Zeneca, Biomerieux, Boehringer Ingelheim, BMS, Brahms, Cardiorentis, Novartis, Roche, Sanofi, Siemens, and Singulex. Professor Hazen and Professor Wang were supported in part by grants from the National Institutes of Health and the Office of Dietary Supplements (P01HL147823, HL103866, HL126827, HL130819 and the Leducq Foundation). Mass spectrometry studies were performed on instruments housed in a facility supported in part by a Center of Excellence Award by Shimadzu Scientific Instruments. Professor Hazen and Professor Wang report being named as co-inventor on pending and issued patents held by the Cleveland Clinic relating to cardiovascular diagnostics and therapeutics and being eligible to receive royalty payments for inventions or discoveries related to cardiovascular diagnostics or therapeutics from Cleveland HeartLab, Quest Diagnostics, and Procter & Gamble. SL Hazen also reports being a paid consultant for Procter & Gamble and having received research funds from Procter & Gamble and Roche Diagnostics.

Figures

Fig. 1
Fig. 1
Levels of TMAO, betaine, choline and carnitine compared between patients adjudicated to have fCAD (A, C, E, G) and compared between patients adjudicated to have fCAD within subgroups of patients with and without history of CAD (B, D, F, H)
Fig. 2
Fig. 2
Kaplan Meier survival analysis of TMAO combined with low and high levels hs-Troponin (below/above URL of 14 ng/L; panel A) and TMAO combined with low and normal ranges of eGFR (> 60 mL/min/1.73m2 considered normal eGFR; panel B—in patients with available eGFR data (n = 921))
Fig. 3
Fig. 3
Time-dependent AUC of ROC of the four markers and over 5-years for all-cause death (223 events), cardiovascular death (115 events), AMI (88 events) and mace (203 events). Each step represents a change in AUC due to an event or censoring. AUC in the first days (ca. 180) vary due to small number of events in early stages
See this image and copyright information in PMC

References

    1. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472:57–63. doi: 10.1038/nature09922. - DOI - PMC - PubMed
    1. Tang WHW, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368:1575–1584. doi: 10.1056/NEJMoa1109400. - DOI - PMC - PubMed
    1. Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19:576–585. doi: 10.1038/nm.3145. - DOI - PMC - PubMed
    1. Roncal C, Martínez-Aguilar E, Orbe J, et al. Trimethylamine (Tma) and trimethylamine-N-oxide (Tmao) as predictors of cardiovascular mortality in peripheral artery disease. Atherosclerosis. 2019 doi: 10.1016/j.atherosclerosis.2019.06.716. - DOI - PMC - PubMed
    1. Jonsson AL, Bäckhed F. Role of gut microbiota in atherosclerosis. Nat Rev Cardiol. 2017;14:79–87. doi: 10.1038/nrcardio.2016.183. - DOI - PubMed

Publication types

Associated data